Company / Revenue per Share
Akebia Therapeutics, Inc. Revenue per Share History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$1.05
FY2025
5-year range
$0.82 / $2.26
FY2021-FY2025
Trend
+27.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue per Share returned to growth in FY2025 after 3 years of decline, reaching $1.05.
Based on SEC 10-K filings.
1.05 in FY2025 with a 5-year CAGR of -9.3%.
Remained stable around $1.05 over the past 2 years.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- -14.0%
- 5-Year CAGR
- -9.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, revenue per share increased 27.6% year-over-year.
- Peak revenue per share was recorded in FY2021.
- Lowest revenue per share in the period was in FY2015.
Company context
Key Data Points
- Altman Z-Score -2.76 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.05 | +27.6% |
| FY2024 | $0.82 | -22.1% |
| FY2023 | $1.06 | -36.0% |
| FY2022 | $1.65 | -27.0% |
| FY2021 | $2.26 | +32.5% |
| FY2020 | $1.71 | +10.1% |
| FY2019 | $1.55 | +4709.2% |
| FY2018 | $0.03 | - |
| FY2015 | $0.00 | - |
| FY2014 | $0.00 | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026